Posts tagged Abbott
Microbix in talks with investors for Kinlytic relaunch

Following a meeting with the FDA last month, Microbix Biosystems (TSX:MBX) is entertaining expressions of interest from potential partners to license or acquire its anti-clotting urokinase drug, which has been rebranded as Kinlytic, and also provide funding for its re-launch in the U.S. market.

Read More
Clerio Vision developing non-invasive laser vision correction

Closely-held Clerio Vision hopes to begin proof-of-concept studies next year of a non-invasive, incision-less and tissue sparing vision correction laser technology that modifies the refractive index of the cornea.

“Our goal is a lunch time laser correction procedure that removes both the fear and potential risks of surgical intervention,” CEO, Mikael Totterman, says in an interview with BioTuesdays.com.

“This procedure can correct near- or far-sightedness, and since it does not remove any tissue, it can also be used to adjust other more invasive treatments such as cataract or LASIK surgeries,” he adds.

Read More